Product Description
Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the body after other treatment(s). Encorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a618040.html)
Mechanisms of Action: BRAF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States
Approved Indications: Colorectal Cancer | Melanoma | Oncology Solid Tumor Unspecified | Oncology Unspecified
Known Adverse Events: Abdominal Pain | Pain Unspecified | Dermatitis | Arthralgia | Melanoma | Diarrhea
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 48
Highest Development Phases
Phase 3: Colorectal Cancer|Melanoma
Phase 2: Adenocarcinoma|Brain Cancer|Multiple Myeloma|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Phase 1: Healthy Volunteers|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-004310-19 | P3 |
Active, not recruiting |
Melanoma |
2035-04-19 |
|
| 2021-000743-41 | P3 |
Active, not recruiting |
Melanoma |
2035-01-21 |
|
| The STARBOARD Study | P3 |
Active, not recruiting |
Melanoma |
2030-06-29 |
|
| BEPCOME-MB | P2 |
Active, not recruiting |
Melanoma |
2030-01-13 |